Hepato-pancreato-biliary

E179: Patient-Derived Organoids Reveal Intrapatient Drug Response Heterogeneity in Pancreatic Neuroendocrine Liver Metastases

E180: Lymph Node Yield at Pancreatectomy is Influenced by Tumor Biology in Addition to Institutional and Surgical Factors

E181: Incidence and Prognostic Value of Actionable Alterations in Early-Stage Resectable Cholangiocarcinoma

E182: Adherens Junction Pathway Genetic Alterations Are Associated with Worse Prognosis in Pancreatic Ductal Adenocarcinoma

E183: Social Vulnerability as a Neighborhood-level Determinant of Pancreatic Cancer Survivorship: A National Analysis of Veterans Affairs Patients

E184: Diabetes promotes pancreatic adenocarcinoma through chitinase-3 like-protein-1 and interleukin-6 signalling

E185: The Circadian Clock Exerts Influence on Pancreatic Cancer Collagen Composition

E186: Targeting IL-6, CXCL12, and TGFB1: A Possible Approach to Suppress Pancreatic Cancer Invasion via Stromal Intervention

E187: The Role of Chemotherapy in the Management of Pancreatic Acinar Cell Carcinoma

E188: Outcomes after resection of solitary colorectal liver metastases: analysis of 535 consecutive cases

E189: Adjuvant Hepatic Arterial Infusion Pump Chemotherapy in Patients with Resectable Colorectal Liver Metastases and Extrahepatic Disease

E190: Association between Patient-Reported Outcomes and Surgical Attrition during Neoadjuvant Therapy for Gastrointestinal Malignancies

E191: Recurrent Intrahepatic Cholangiocarcinoma: A Novel Prognostic Model to Predict Post-Recurrence Survival and Guide Treatment of Recurrence

E192: Re-evaluating the Role of Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival

E193: Expanding immunotherapy options in cholangiocarcinoma: Role of CD27 agonist in combination with PD-L1 and MEK inhibition on antitumor effect and CD8+ T cells

E194: Patient-Derived Biliary Tract Cancer Organoid Biobank: Is Personalized Medicine Utilizing Organoids Feasible for Patients with Cholangiocarcinoma?

E195: Irreversible Electroporation in Combination with Adjuvant PD-1 Versus TIGIT Checkpoint Inhibition in an Orthotopic Pancreatic Cancer Model

E196: Exploring the Role of Health-Related Quality of Life in Surgical Decision Making for Pancreatobiliary Patients

E197: Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics and Survival

E198: Analysis of Extracellular Vesicle Protein Profiles to Predict Treatment Response in a Phase II Clinical Trial with Cabozantinib and Pembrolizumab for Refractory Metastatic Pancreatic Cancer

E199: Black Race and CA 19-9 Nonproduction is Associated with Limited Pathologic Response to Neoadjuvant Chemotherapy in Patients with Localized Pancreatic Cancer

E200: Single Cell Multiomic Sequencing with Bioinformatic Analysis Identifies Dynamic Transcriptional and Epigenetic Changes During Metastasis of Pancreatic Cancer

E201: TAK-981 Synergizes with Cytotoxic and Targeted Therapy in Patient Derived Organoid Models of Pancreatic Cancer

E202: The Association of Pre-Hepatic Artery Infusion Pump Systemic Chemotherapy with Intrahepatic Floxuridine Tolerance

E203: SSI Prophylaxis with 1st Generation Cephalosporins is Non-inferior to Broad-spectrum Antibiotics in Distal Pancreatectomy

E204: Stage-for-Stage Survival is Equivalent After Multiagent Neoadjuvant Therapy Compared to Upfront Surgery Followed by Multiagent Adjuvant Chemotherapy in Over 2900 Patients with Pancreatic Cancer

E205: Preclinical evaluation of NOTCH inhibition to enhance PD-1 immunotherapy in pancreatic cancer

E207: Safe Successful Surgery: Re-visiting survival outcomes defined by margin status in the era of neoadjuvant therapy utilization in pancreatic ductal adenocarcinoma

E208: Pre-operative biomarkers may predict nodal status in pancreas adenocarcinoma

E209: Machine Learning to Predict Early Death Despite Pancreaticoduodenectomy

E210: Circulating Tumor DNA in Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma

E211: Plasma biomarkers for early-stage MASH-HCC detection

E212: Treatment with anti-Semaphorin4D To Modulate Response of Pancreatic Adenocarcinoma to Immunotherapy

E213: Fragmented Care in Pancreatic Cancer Treatment: Bridging Gaps for Improved Patient Related Outcomes

E214: Inter-reader agreement of imaging response after neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma

E215: Patient Expectations about the Oncologic Benefit of Surgery Among Patients Undergoing Pancreatectomy for Pancreatic Cancer

E216: Correlation of DOTATATE PET-CT Uptake, Pathologic Grade, and ATRX/DAXX Loss of Expression in Localized Non-Metastatic Pancreatic Neuroendocrine Tumors

E217: Incomplete Cytoreduction and Major Hepatectomy are Associated with Worse Survival in Patients Undergoing Combined Cytoreductive Surgery and Hepatectomy for Metastatic Colorectal Cancer

E218: Genomic Classification of Ampullary Adenocarcinoma to Guide Adjuvant Treatment Selection

E219: Combined Radiofrequency Ablation with Liver Resection for Colorectal Cancer Liver Metastasis: A Nationwide Survival Analysis

E220: TIGIT expression increases with advancing clinical stages of resected pancreatic cancer

E221: Pre-operative liquid biopsy for optimal patient selection in metastatic colorectal cancer: techniques to avoid futile liver resections

E222: Using pH as a Biomarker for Imaging of Pancreatic Cancer

E223: Vascular Involvement in Pancreas Cancer: Limitations of Relying on Imaging and Expert Opinion

E224: Rates of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Therapy

E225: Surgeon Communication of Prognosis in Pancreatic Cancer: A Single-Institution Pilot Study Using the VitalTalk ADAPT Framework

E226: Human Glypican-3-Targeted Zirconium-89 Immuno-Positron Emission Tomography for Hepatocellular Carcinoma

E227: Characterizing Conditional 90-Day Mortality and Associated Risk Factors Following Hepatobiliary and Pancreatic Cancer Surgery

E228: Perioperative and oncologic outcomes of hepatic arterial infusion pump chemotherapy for patients with unresectable colorectal liver metastases at an expanding HAI program

E229: Surveillance-Associated Anxiety Following Curative-Intent Cancer Surgery: A Mixed Methods Analysis

E230: Impact of initial resectability and neoadjuvant chemotherapy on overall survival for pancreatic adenocarcinoma

E231: Analysis of Pancreas Multidisciplinary Tumor Board: Do Presented Patients Receive More Appropriate Care?

E232: Utility of Intraoperative Bile Duct Cultures in Pancreaticoduodenectomy After Preoperative Stenting

E233: Circulating Tumor DNA (ctDNA) is an Independent Predictor for Disease Recurrence Following Resection of Colorectal Liver Oligometastases

E234: Feasibility and Utility of Dynamic ctDNA Profiling in Patients with Pancreatic Adenocarcinoma in a Neoadjuvant Setting

E235: Clinicopathologic Risk Factors Affecting Pancreatic Fistula Formation after Enucleation of Pancreatic Neoplasms

E236: National Trends in Robotic Pancreaticoduodenectomy – A national database analysis

E237: Robotic Assisted Pancreaticoduodenectomy Does Not Impact Receipt of or Time to Adjuvant Chemotherapy Compared to an Open Surgical Approach

E238: A Novel Scoring System to Predict Neoadjuvant Treatment Efficacy in Pancreatic Adenocarcinoma

E239: A National Cancer Survival Calculator for Hepatobiliary Cancers using Machine Learning

E240: Impact of Clonorchis sinensis on gut microbiome in liver cancer patients

E241: Trends in the Use of Observation for Small Nonfunctional Pancreatic Neuroendocrine Tumors

E242: Circulating Tumor DNA in Patients Undergoing Liver Transplant for Hepatocellular Carcinoma, Cholangiocarcinoma, and Colorectal Liver Metastases

E243: Clinical Impact of Tumor Mutational Profiling in Resected Pancreatic Cancer: A Single Institution Experience

E244: Cost analysis and financial implications of robotic and open pancreatoduodenectomy: a propensity score-matched analysis

E245: Determining risks of false negative nodal staging in pancreatic cancer following neoadjuvant therapy and surgery

E246: A Novel Model of Resectable Pancreatic Cancer Reveals Circadian Rhythm Genes Dec2 and BMAL1 as Novel Therapeutic Targets to Increase Survival by Immune Activation

E247: A Deep Learning Approach to Predict Response to Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma

E248: High Estrogen receptor gene (ESR1) expression is associated with less cell proliferation and better outcomes in Hepatocellular Carcinoma patients.

E249: Estimating Care Fragmentation in Pancreatic Cancer

E250: Prospective Evaluation of the Safety and Quality of Life in Patients Receiving Hepatic Artery Infusion Pump Chemotherapy

E251: The Inflation-adjusted Decline of Medicare Reimbursement in Hepatobiliary Surgery (2003-2023)

E252: Circulating Tumor DNA in Pancreas Cancer Patients Receiving Neoadjuvant Therapy: Preliminary Results from a Prospective Study

E253: Handgrip strength is associated with pancreatic fistula following pancreatectomy and may predict inoperable disease

E254: Survival and Downstaging After Neoadjuvant Therapy for Hepatocellular Carcinoma: A Propensity-Matched Analysis of the National Cancer Database

E255: The Impact of Neighborhood Socioeconomic Deprivation on Treatment for Resectable Pancreatic Cancer Patients in Florida: An Incidence-Based Retrospective Cohort Study

E256: Characterization and Natural Evolution of Mixed Adeno-neuroendocrine Carcinoma of the Pancreas

E257: Temporal Trends and the Impact of Fragmented Care in those with Pancreatic Cancer

E258: Survival Benefit of Adjuvant Chemotherapy in Resected Squamous Carcinoma of the Gallbladder

E259: Prevalence of Pathogenic Variants on Pharmacogenomic Testing Prior to Initiation of Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma

E260: Impact of duration of neoadjuvant therapy on pathologic and clinical outcomes for pancreatic adenocarcinoma

E261: Travel Distance from Primary Residence to Hospital Affects the Length of Stay for Patients Undergoing Major Pancreatic Surgery

E262: Prognostic Significance of Lymph Node Ratio in Intrahepatic and Extrahepatic Cholangiocarcinomas

E263: The Oncology Landmark Series: The Top Articles A Trainee Should Know About The Surgical Management Of Cholangiocarcinoma

E264: Association of Blood Transfusion During Surgery for Colorectal Liver Metastasis with Outcomes: Propensity Score Analysis of Multicenter Database

E265: Intraoperative Frozen Pathology is Highly Concordant with Permanent Histopathology

E267: Use of Machine Learning in Prediction of Completion of Treatment for Pancreatic Cancer

E268: Progression of Small Intraductal Papillary Mucinous Neoplasms and Undefined Cysts of the Pancreas: A Systematic Review

E269: Neoadjuvant Chemotherapy in Resected Cholangiocarcinoma: Insights from the National Cancer Database

E270: Decreased Primary Tumor Th2 Cell Tumor Infiltration is Associated with Liver Metastases Across Cancer Types

E271: Small non-functioning pancreatic neuroendocrine tumors: practice patterns and trends in a national cohort

E272: Has management of locally advanced intrahepatic cholangiocarcinoma evolved with the evidence? Trends and practice patterns from the National Cancer Database

E273: Neoadjuvant Chemotherapy May Be Key to Improving Mortality and Survival for Octogenarians with Pancreatic Ductal Adenocarcinoma

E275: Multiagent Adjuvant Chemotherapy Associated with Improved Overall Survival in Resected Ampullary Adenocarcinoma

E276: Risk factors associated with positive resection margins in patients with gallbladder adenocarcinoma

E277: The Role of Neighborhood Socioeconomic Deprivation on Overall Survival for Stage I/II Hepatocellular Carcinoma Patients in Florida: An Incidence-Based Retrospective Cohort Study

E278: Impact of neoadjuvant chemotherapy on post-hepatectomy outcomes for colorectal liver metastasis

E279: Does the resolution or development of sarcopenia following neoadjuvant therapy for pancreatic adenocarcinoma correlate with pathologic tumor response?

E280: The Association of Neighborhood Socioeconomic Deprivation and Treatment for Stage I/II Hepatocellular Carcinoma in Florida: An Incidence-Based Retrospective Cohort Study

E281: The Importance of Biliary Spillage during Cholecystectomy for Gall Bladder Adenocarcinoma: A Systematic Review and Meta-analysis

E282: Factors influencing surgical management and survival in gallbladder cancer – A SEER-Medicare based study

E283: Temporal Trends in the Surgical Treatment of Pancreatic Ductal Adenocarcinoma in the US

E284: Distal Pancreatectomy With and Without Celiac Axis Resection for Adenocarcinoma: A Comparison in the Era of Neoadjuvant Therapy

E285: Older Age Does Not Increase Inpatient Complications After Pancreatectomy

E286: Synoptic Preoperative Evaluation Of Hepatopancreaticobiliary Cancer: An Institutional Experience

E287: Trends in the Utilization of Neoadjuvant Therapy and its Impact on Vascular Resection Among Patients Undergoing Resection for Pancreatic Adenocarcinoma

E288: Patient Selection and Outcomes with Hepatic Artery Infusion Chemotherapy (HAIC) in Unresectable Colorectal Liver Metastasis (uCRLM) at a Tertiary Referral Center

E289: Open Vs Robotic Hepatectomy For Primary Hepatobiliary Malignancy: Validated Outcomes And Survival Analysis

E290: Frailty and Oncologic Outcomes in Pancreatic Cancer: A Comparative Analysis of Frail and Non-Frail Patients

E292: Single Versus Multiagent Chemotherapy for Ampullary Carcinoma: A Multivariate Analysis of the NCDB

E293: Irreversible Electroporation as a Potential Adjunct for Locally Advanced Pancreatic Cancer

E294: Association of Sex and Obesity on Overall Survival in Patients Undergoing Upfront Surgery for Resectable Pancreatic Adenocarcinoma

E295: Robotic Major and Minor Hepatectomy: Impact of clinicopathologic factors on perioperative and short-term outcomes

E296: Outcomes of hepatic artery-based therapies and systemic multiagent chemotherapy in unresectable colorectal liver metastasis: A systematic review and meta-analysis

E297: Robotic versus Open major hepatectomy: A single center matched comparison of outcomes.

E298: Complete Primary Pathological Response Following Neoadjuvant Therapy in Patients Undergoing Major Pancreatic Resection

E299: Pancreaticoduodenectomy indications, intraoperative difficulties and early postoperative complications in limited resources, a prospective study in Yemen

E300: Surgical resection may improve survival in oligometastatic pancreatic cancer following systemic therapy

E373: P53 Gain/Loss of Function Status Correlates with Overall Survival in Patients with Resected Pancreatic Cancer

P30: Aryl Hydrocarbon Receptor Ligands Found in Cigarette Smoke Drive Pancreatic Cancer Via Pro-Tumorigenic T Cell Polarization

P31: Survival of Patients with Microsatellite Instability-High and Lynch Syndrome-Associated Pancreatic Ductal Adenocarcinomas

P32: JNK inhibition reprograms the tumor-immune-microenvironment to overcome chemoresistance in PDAC

P33: The Role of Human Adipocytes Derived Extracellular Vesicles in Mediating Pancreatic Cancer Growth and Angiogenesis

P34: Utilization of Deep Learning Algorithms for Predicting Positive Portal/Superior Mesenteric Vein Margin in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Adenocarcinoma

P35: Extrahepatic Cholangiocarcinoma: Genomic Variables Associated with Anatomical Location and Outcome

P36: Increased Efficacy of a Synergistic Combination in Sensitizing Pancreatic Neuroendocrine Tumors to Radiation in vivo

P37: CA 19-9 Normalization Following Neoadjuvant Therapy and Yield of Laparoscopy for Pancreatic Ductal Adenocarcinoma